Biodesix will present seven abstracts at AACR 2026, showcasing innovations in cancer diagnostics and monitoring technologies.
Quiver AI Summary
Biodesix, Inc., a diagnostics solutions company, will present seven abstracts, including two oral sessions, at the AACR Annual Meeting in San Diego from April 17-22, 2026. These presentations will highlight Biodesix's expertise in blood- and tissue-based testing across various applications, showcasing advancements in genomic and proteomic technologies, alongside their capabilities in tumor and immune profiling. The company has also validated a new clinical myeloid panel that delivers sequencing results quickly. Notably, collaborative presentations will focus on monitoring molecular residual disease (MRD) and highlight innovative approaches and technologies in this field. Biodesix’s commitment to improving clinical care and outcomes is underscored by their extensive experience in developing diagnostic tests and services for biopharmaceutical and life science partners.
Potential Positives
- Biodesix will present seven abstracts, including two oral sessions, at the prestigious AACR Annual Meeting, showcasing their expertise in diagnostics.
- The presentations highlight advancements in blood- and tissue-based testing, indicating strong technological capabilities that could enhance partnerships in biotech and life sciences.
- Biodesix has validated a new clinical myeloid panel that can deliver sequencing results in as little as 24 hours, demonstrating their commitment to rapid and effective diagnostics.
- The company’s focus on tumor and immune profiling, along with a novel multi-omic approach, positions them at the forefront of innovative cancer monitoring solutions.
Potential Negatives
- Press release may imply a lack of groundbreaking new data, as it focuses on the presentation of existing capabilities and products rather than unveiling new innovations or studies, which could be perceived as a sign of stagnation.
- Emphasis on partnerships and collaborations could suggest that the company is reliant on external organizations for research and validation, raising concerns about its independent capabilities and innovation.
- The absence of specific performance data or outcomes in the press release raises questions regarding the effectiveness and reliability of the diagnostics being presented, which could impact trust and confidence among investors and partners.
FAQ
What will Biodesix present at the AACR Annual Meeting 2026?
Biodesix will present seven abstracts, including two oral presentations, focused on blood- and tissue-based testing and monitoring.
When is the AACR Annual Meeting taking place?
The AACR Annual Meeting will be held from April 17 to 22, 2026, in San Diego, CA.
What technologies will Biodesix showcase?
Biodesix will highlight mass spectrometry, Bio-Rad ddPCR™, and Thermo Fisher Ion AmpliSeq™ technologies for tumor and immune profiling.
What is the focus of Biodesix's MRD pipeline presentations?
Biodesix's MRD pipeline presentations will discuss a multi-omic approach to monitoring molecular residual disease using proteomic and genomic biomarkers.
Where can I find more information about Biodesix's AACR presentations?
The full abstracts and details about Biodesix's presentations can be found on their official website.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BDSX Insider Trading Activity
$BDSX insiders have traded $BDSX stock on the open market 23 times in the past 6 months. Of those trades, 3 have been purchases and 20 have been sales.
Here’s a breakdown of recent trading of $BDSX stock by insiders over the last 6 months:
- JACK W SCHULER has made 3 purchases buying 182,465 shares for an estimated $2,084,296 and 0 sales.
- SCOTT HUTTON (President & CEO) has made 0 purchases and 4 sales selling 6,208 shares for an estimated $64,269.
- ROBIN HARPER COWIE (CFO, Sec'y & Treasurer) has made 0 purchases and 4 sales selling 1,824 shares for an estimated $19,133.
- KIERAN O'KANE (Chief Commercial Officer) has made 0 purchases and 4 sales selling 1,442 shares for an estimated $15,343.
- GARY ANTHONY PESTANO (Chief Development Officer) has made 0 purchases and 4 sales selling 1,417 shares for an estimated $15,152.
- CHRIS VAZQUEZ (Chief Accounting Officer) has made 0 purchases and 4 sales selling 408 shares for an estimated $4,489.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BDSX Revenue
$BDSX had revenues of $28.8M in Q4 2025. This is an increase of 40.76% from the same period in the prior year.
You can track BDSX financials on Quiver Quantitative's BDSX stock page.
$BDSX Hedge Fund Activity
We have seen 12 institutional investors add shares of $BDSX stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ABERDEEN GROUP PLC added 262,425 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,784,490
- TELEMARK ASSET MANAGEMENT, LLC removed 86,300 shares (-20.8%) from their portfolio in Q4 2025, for an estimated $586,840
- SILVERARC CAPITAL MANAGEMENT, LLC removed 49,607 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $337,327
- SHAY CAPITAL LLC removed 39,875 shares (-71.2%) from their portfolio in Q4 2025, for an estimated $271,150
- TREXQUANT INVESTMENT LP added 27,542 shares (+inf%) to their portfolio in Q4 2025, for an estimated $187,285
- CITADEL ADVISORS LLC added 25,985 shares (+inf%) to their portfolio in Q4 2025, for an estimated $176,698
- GSA CAPITAL PARTNERS LLP added 16,141 shares (+33.4%) to their portfolio in Q4 2025, for an estimated $109,758
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BDSX Analyst Ratings
Wall Street analysts have issued reports on $BDSX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 02/27/2026
To track analyst ratings and price targets for $BDSX, check out Quiver Quantitative's $BDSX forecast page.
Full Release
LOUISVILLE, Colo., April 06, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 - 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.
“Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics,” said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.
“The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR. It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026,” said Scott Hutton, CEO, Biodesix.
Tumor & Immune Profiling Expertise
Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR™, and Thermo Fisher Ion AmpliSeq ™ platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent™ Genexus™ System . The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.
Sunday, April 19 | 3PM–5PM PST | Oral Presentation | Room 17, Mezzanine Level, Convention Center
Title
: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations
Monday, April 20 | 2PM–5PM PST | Poster Section 41
Poster:
3743. ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR™ (ddPCR™) panel for ultra-sensitive NSCLC biomarker detection
Wednesday, April 22 | 9AM–12PM PST | Poster Section 39
Poster
: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer
Monday, April 20 | 2PM–5PM PST | Poster Section 44
Title
: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system
Molecular Residual Disease (MRD) Product Pipeline
Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.
Monday, April 20 | 12:30PM | Spotlight Theater B - Sails Pavilion - Conv Ctr
Title
: Leveraging Droplet Digital PCR™* (ddPCR™) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies
Tuesday, April 21 | 2PM–5PM PST | Poster Section 1
Poster
: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.
Wednesday, April 22 | 9AM–12PM PST | Poster Section 45
Poster:
7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs
The full abstracts for Biodesix and a list of all abstracts being presented at the AACR Annual Meeting can be found here .
- ddPCR™ technology is a trademark of Bio-Rad Laboratories, Inc.
- Ion Torrent™ Genexus ® System and Ion AmpliSeq™ Platform are trademarks of Thermo Fisher Scientific.
-
NSCLC is the acronym for Non-Small Cell Lung Cancer.
About Biodesix:
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests , marketed as Nodify Lung ® Nodule Risk Assessment and IQLung ® Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.
Biodesix Contacts:
Media:
Natalie St. Denis, Director Corporate Communications
[email protected]
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR
[email protected]
(339) 970-2843
